Transient T cell immunodeficiency is a common complication following hematopoietic stem cell transplantation. In breast cancer patients transplanted with autologous peripheral blood progenitor cells (PBPC) harvested after cytotoxic treatment with either cyclophosphamide or epirubicin plus paclitaxel, we evaluated T cells infused in grafts and in peripheral blood during the early reconstitution phase. We found that PBPC grafts harvested after treatment with epirubicin plus paclitaxel contained substantially larger numbers of T cells with less altered composition than after cyclophosphamide. Three months after high-dose cytotoxic chemotherapy, the numbers and the kinetics of circulating naive T cells, but not of memory and CD28À T cells, correlated positively with the number of naive T cells infused PBPC grafts. Finally, retrospective analysis of two cohorts of patients transplanted in different clinical settings with PBPC grafts harvested following cyclophosphamide or epirubicin plus paclitaxel showed apparently different susceptibilities to develop endogenous varicella zoster virus reactivation in the first year after high-dose cytotoxic chemotherapy. On the whole, these data indicate that number and composition of T cells in PBPC grafts vary according to the former cytotoxic therapy, and suggest that autologous transfer of T cells may accelerate the early T cell reconstitution phase and possibly ameliorate immune competence in patients rendered lymphopenic by high-dose chemotherapy. Bone Marrow Transplantation (2003) 31, 31-38. doi:10.1038/sj.bmt.1703782 Keywords: T lymphocytes; immunodeficiency; autologous hematopoietic cell transplantation; cell therapy; cytotoxic chemotherapy; immunotherapy Acute T cell depletion is a common complication occurring after high-dose chemotherapy (HD-ChT) with autologous hematopoietic stem cell transplantation.
Summary:
Transient T cell immunodeficiency is a common complication following hematopoietic stem cell transplantation. In breast cancer patients transplanted with autologous peripheral blood progenitor cells (PBPC) harvested after cytotoxic treatment with either cyclophosphamide or epirubicin plus paclitaxel, we evaluated T cells infused in grafts and in peripheral blood during the early reconstitution phase. We found that PBPC grafts harvested after treatment with epirubicin plus paclitaxel contained substantially larger numbers of T cells with less altered composition than after cyclophosphamide. Three months after high-dose cytotoxic chemotherapy, the numbers and the kinetics of circulating naive T cells, but not of memory and CD28À T cells, correlated positively with the number of naive T cells infused PBPC grafts. Finally, retrospective analysis of two cohorts of patients transplanted in different clinical settings with PBPC grafts harvested following cyclophosphamide or epirubicin plus paclitaxel showed apparently different susceptibilities to develop endogenous varicella zoster virus reactivation in the first year after high-dose cytotoxic chemotherapy. On the whole, these data indicate that number and composition of T cells in PBPC grafts vary according to the former cytotoxic therapy, and suggest that autologous transfer of T cells may accelerate the early T cell reconstitution phase and possibly ameliorate immune competence in patients rendered lymphopenic by high-dose chemotherapy. Acute T cell depletion is a common complication occurring after high-dose chemotherapy (HD-ChT) with autologous hematopoietic stem cell transplantation. 1 In spite of the rapid recovery of myelopoiesis allowed by infusion of peripheral blood progenitor cells (PBPC) and myelopoietic growth factors, recovery of total T cell numbers to baseline values is more gradual since it usually takes at least 3 months. 2 However, peripheral T cells in the early reconstitution phase invariably show an abnormal inversion of the CD4/CD8 ratio lasting several months or even longer, which is mainly because of an increase in atypical CD8+ T cells. 3 In this regard, we have recently documented that CD8+ T cells exceeding CD4+ T cells and accounting for such inversion, are constituted by a compensatory expansion of CD8+CD28À T cells 4 whose TcR diversity and potential for immune competence are reportedly limited. 5, 6 Consistently, notwithstanding normal WBC values, in the early phase of recovery from HD-ChT, patients are susceptible to opportunistic infections such as Pneumocysti carinii, to endogenous reactivation of varicella zoster virus (VZV), and are not readily eligible for vaccination protocols. 7 Thus, specific approaches to enhance early recovery of CD28+ T cells after HD-ChT are necessary in order to abbreviate T cell immunodeficiency.
Mature CD28+ T cells with high diversity of the TcR repertoire can be supplied through the thymus-dependent pathway via thymic differentiation of primitive marrowderived progenitors. Alternatively, homeostatic pressure in lymphopenic hosts can also induce proliferative expansion of mature pre-existing peripheral precursors. 8 After acute and maximal damage induced by HD-ChT, both these regenerative pathways can contribute to the recovery of a peripheral T cell pool, but the contribution by thymusdependent regeneration is inevitably delayed and of limited quantity in adults. 9 By contrast, proliferative expansion of post-thymic mature T cells cannot increase the diversity for antigen specificity, but it can provide an early and relatively rapid increase of the bulk number of T cells. Under these circumstances, the composition of the starting pool of T cells undergoing homeostatic proliferative expansion might have a substantial impact on T cell reconstitution in the early phase of recovery from HD-ChT.
The starting pool of mature post-thymic T cells circulating in peripheral blood after HD-ChT, followed by infusion of PBPC, derives from two main sources: T cells transferred with the PBPC graft after HD-ChT, or T cells that have survived the cytotoxic conditioning regimen. 1 Previous studies demonstrated that passively transferred T lymphocytes in the allogeneic setting will contribute to sustained cellular immunity, 10 while other studies in the autologous setting suggested that quantity of T cells present in the graft might influence the rapidity and the quality of T cell recovery. 11 However, Mackall et al showed more recently that mature CD4+ T cells in the grafts do not appear to contribute substantially to immune reconstitution. 12 Therefore, it remains unclear how much passively transferred T lymphocytes will contribute to T cell reconstitution after autologous transplantation with PBPC.
Recently, we 4,13,14 and others 15, 16 have proposed that phenotypic evaluation of circulating T cells should consider separation of memory and effector T cell subsets since they bear remarkably different potential for proliferative expansion and TcR diversity. In the current study, we have asked whether cytotoxic therapy with either cyclophosphamide (CTX), or epirubicin plus paclitaxel (ET), may affect the number of these T cells subsets in PBPC grafts harvested following mobilization with G-CSF. Accordingly, we also looked for possible correlations between the amounts of each T cell subset infused with its own reconstitution in peripheral blood during the early post-transplantation phase of patients infused by the two different types of PBPC grafts. Finally, we re-examined clinical records concerning endogenous VZV reactivation in the first year after transplantation of both patients treated for primary and advanced breast cancer, respectively, infused with PBPC harvested following cytotoxic chemotherapy with CTX and ET.
Materials and methods

Study subjects and clinical protocols
The study population comprised patients with breast cancer referred to Salvatore Maugeri Foundation Pavia Medical Center. All but two patients with primary breast cancer, received a mobilizing regimen with cyclophosphamide (4-7 g/m 2 ) plus filgrastim (5 mg/kg/day) starting 48 h after chemotherapy and administered until a total of at least 5 Â 10 6 CD34+cells/kg body weight could be harvested by leukapheresis. The myeloablative regimen consisted of thiotepa (600 mg/m 2 ) on day À3, and melphalan (160 mg/m 2 ) on day À1. In two patients with primary breast cancer, an alternative protocol was inaugurated with mobilizing regimen consisting of epirubicin (90 mg/m 2 ) and paclitaxel (175 mg/m 2 ) plus filgrastim, as previously described, 17 while myeloablation was induced by administration of mitoxantrone (60 mg/m 2 ) on day À5, thiotepa (500 mg/m 2 ) on days À4 to À2, and cyclophosphamide (6 g/m 2 ) on days À4 to À2. Patients with metastatic breast cancer responsive to induction chemotherapy, received the same mobilizing regimen administered to these two latter patients with primary breast cancer, consisting of epirubicin (90 mg/m 2 ) and paclitaxel (175 mg/m 2 ) plus filgrastim. Myeloablation was similarly induced by administration of mitoxantrone, thiotepa and cyclophosphamide. Autologous PBPC were thawed and reinfused on day 0 in all patients. A median of 6.75 Â 10 6 CD34+cells/kg was reinfused and filgrastim was administered at daily dose of 5 mg/kg from day 0 until hematological recovery, defined as total white blood cells 4500/ml and platelets 420 000/ml. After the completion of therapy, evaluated patients with primary breast cancer were without evidence of disease when tested, whereas patients with metastatic breast cancer were not showing disease progression. Median age of all treated patients was 46 years and performance status was good (o1 WHO) in the majority.
Collection of autologous peripheral blood progenitor cells (PBPC)
PBPC collection from breast cancer patients undergoing high-dose chemotherapy was performed by Cobe Spectra as previously reported 18 so as to achieve a minimum target CD34+cell dose of 5 Â 10 6 /kg patient's body weight. Collected PBPC were cryopreserved in autologous plasma and 10% DMSO using controlled-rate freezing and stored in liquid nitrogen until thawing in bags for reinfusion in patients and in pilot vials for analysis, as previously described. 17 We analyzed percentages and absolute T cell numbers and T cell subpopulations in 15 PBPC grafts from patients pretreated with CTX as compared to another group of 15 PBPC grafts from patients pretreated with ET.
Evaluation of T cells from peripheral blood
Evaluation of lymphocyte subsets was undertaken at the time of routine clinic visits that occurred at 1, 3, 6, 9 months during the first year after high-dose chemotherapy. To this end, 10 ml of peripheral blood were harvested from each patients in heparinized tubes by venipuncture. Absolute numbers of CD3+ T cells were determined directly on red cell-lysed whole blood by single-platform flow cytometric method, as described in the following section. Thereafter, peripheral blood mononuclear cells (PBMC) were separated by Ficoll-Hypaque density gradients. PBMC were tested immediately for flow cytometry analysis of T cell subsets as described later. Using such methodology, we evaluated prospectively 10 consecutive patients, of whom six had been transplanted in the adjuvant setting with PBPC harvested after CTX and four had been transplanted with PBPC harvested after ET (two patients in the adjuvant setting and two with stage IV breast cancer).
Evaluation of CD3+ absolute cell numbers by flow cytometry analysis
Absolute cell numbers in thawed PBPC as well as peripheral blood were determined by a single-platform flow cytometry method using TruCOUNTt absolute count tubes (BDIS, Becton Dickinson Immunochemistry Systems, San Jose, CA, USA), according to the manufacturer's instructions. Single-platform TruCOUNTt method based on flow cytometry can provide an accurate absolute count even with low numbers of white blood cells while reducing potential imprecision and variability of automated hema-tology counts. 19 This protocol is based on the use of tubes containing a fixed number of lyophilized fluorescent beads acting as an internal standard for absolute counts. Accordingly, for cell number calculations, 50 ml of cell suspension were accurately measured, added into tubes, and incubated with the probe LDS-751 (Exciton, Dayton, OH, USA) and with monoclonal antibodies. LDS-751 expression in the FL3 channel was used to set the threshold to exclude debris and non-nucleated molecules. The absolute number of CD34+ and CD3+ cells were obtained, respectively, by adding test tubes with the following combinations of monoclonal antibodies purchased from BD Pharmingen (San Diego, CA, USA): FITC-CD45 (clone 2D1, mouse IgG1,k) and PE-CD34 (clone 581 mouse IgG1, k), or FITC-CD45 and PE-CD3 (clone UCHT1, mouse IgG1, k). After staining, red cells were lysed with a solution containing ammonium-choride (NH 4 Cl 8.29 g/l, KHCO 3 1 g/l, 4 Â NaEDTA 0.037 g/l, pH 7.4) for 15 min in the dark on ice, and finally the cells were mixed gently and immediately analyzed by flow cytometry. When evaluating numbers of T cells from PBPC, viability was also assessed separately by addition of the dye 7-amino-actinomycin D (Calbiochem, San Diego, CA, USA) at a final concentration of 1 mg/ml. For flow cytometry, 50 000 CD45+ events were collected and analyzed on an FACScan flow cytometer equipped with CellQuest software (BDIS, San Jose, CA, USA).
Analysis of T cell subsets by flow cytometry
For T cell subset analysis, the following monoclonal antibodies were obtained from BD Pharmingen (San Diego, CA, USA): FITC-conjugated anti-CD4 (clone RPA-T4, mouse IgG1, k), -CD45RA (clone HI100, mouse IgG2b, k), -CD95 (clone DX2, mouse IgG1, k); PEconjugated anti-CD8 (HIT 8a, mouse IgG1, k), -CD62L (clone DREG-56, mouse IgG1, k), -CD28 (clone CD28.2, mouse IgG1, k); CyChromeTM-conjugated anti-CD3 (clone UCHT1, mouse IgG1, k), -CD4 (clone RPA-T4, mouse IgG1, k), -CD8 (clone HIT8a, mouse IgG1, k). IgG1 or IgG2b of irrelevant specificity, conjugated to FITC-, PE-, or CyChromeTM were purchased from the same manufacturer, and were used for setting quadrants and gate limits of nonspecific immunoglobulin cell binding (negative control).
To evaluate each distinct T cell subset, PBMC or PBPC was washed in an FCS-containing medium, suspended in PBS plus 10% FBS, 10% human serum and 0.01% sodium azide, and stained for 30 min on ice in the dark with saturating amounts of three fluorochrome-conjugated mAbs (FITC, PE, and Cy-Chromet). Thereafter, stained cells were washed and analyzed by flow cytometry. Instrument compensation was defined preliminarily by acquisition of cell samples individually stained with each fluorochrome-conjugated mAb and further by acquisition of cell samples by mixing 2 Â 2 and finally 3 Â 3 different single stain, bright positive controls. For each sample, 1-2 Â 10 4 viable CD3+ T cells were identified and collected by characteristic low side scatter vs CD3+ profile. To obtain percentages, an electronic gate was placed on CD3+ cells and a correlated expression of CD4+ or CD8+ allowed calculation of percentages and absolute numbers of CD3+CD4+ and CD3+CD8+ multiplying by the CD3+ absolute count obtained with TruCOUNTt tubes. For other subset frequencies, PBPC and PBMC were stained with either CyChromet-conjugated anti-CD3, anti-CD4, anti-CD8 along both anti-CD95-FITC and anti-CD28-PE or anti-CD45RA-FITC and anti-CD62L
Statistical analysis
Comparison between groups was done by two-tailed unpaired Mann-Whitney U-test. Correlation between absolute cell numbers in thawed PBPC and peripheral blood T cells was tested by Spearman's correlation coefficient. In all cases, P value lower than 0.05 was considered significant.
Results
Evaluation of T cell subsets harvested in PBPC grafts of patients with breast cancer
Initially, we evaluated T cell composition in autologous PBPC grafts harvested from patients with high-risk or metastatic breast cancer. To this end, in both CD4+ and CD8+ T cells, we distinguished three main subsets in relation to their developmental stage and activation state. Regarding developmental stage, evaluation of CD28 differentiation antigen allowed to isolate the extensively studied, yet aberrant, CD28-terminally differentiated effector T cell subpopulation (Figure 1) . In fact, CD28À T cells are known as a population bearing restricted TCR repertoire and containing expanded clones, but expressing high levels of CD45RA, namely a marker formerly assumed to be expressed uniquely by naive T cells. Regarding activation state, CD28+ T cells could be divided into resting and activated T cells on the basis of their expression of the CD95 activation molecule. Consistently, as we have already shown in peripheral blood of normal subjects 13 and patients with breast cancer, 4 CD95ÀCD28+ T cells were approximately equivalent to CD45RA+CD62l+ T cells, that are commonly recognized as naive T cells. 20 Thus, as shown in Figure 1 , phenotypic analysis of CD4+ and CD8+ T cells from thawed samples of PBPC apheresis allowed to identify naive T cells either as a CD45RA+CD62L+ or as a CD95-CD28+ population. Furthermore, when differential expression of CD28 and CD95 was used, both CD28À T cells and a third population of CD95+CD28+ presumed memory T cells could also be identified.
When we compared stainings on PBPC from distinct patients randomly selected, we found striking evidence that naive T cells were almost absent in samples harvested after standard regimen with CTX, as compared to alternative regimen with ET ( Figure 1) . Therefore, we went on to confirm that the proportion of T cells and their composition were markedly different in the two types of PBPC grafts. As shown in Figure 2 , frequency of T cells was significantly lower in PBPC harvested after CTX than after ET and naive T cells appeared relatively more altered than memory cells. Finally, we also measured the number of T cells contained in each PBPC graft by evaluating directly, with TruCOUNTt absolute count tubes, the number of viable cells per volume after thawing. As shown in Table 1 , we found significant differences between the two groups of grafts for all T cell subsets evaluated. These data indicated that PBPC grafts harvested after alternative treatment with ET chemotherapy still retained high numbers of T cells with a normal proportion of naive T cells. In contrast, PBPC harvested after standard treatment with CTX contained much lower numbers of T cells with an even lower proportion of the naive subset, thus further supporting the notion that CTX exerts its immunosuppressive effect at least in part through cytotoxicity on T cells, including resting naive T cells.
Evaluation of circulating naive, memory, and CD28À T cells in patients transplanted with PBPC grafts harvested after CTX or ET
We asked whether higher numbers of T cells in PBPC grafts may influence T cell reconstitution after HD-ChT. Results obtained by monitoring circulating T cell subsets for at least 9 months at defined time points after HD-ChT, Figure 1 Identification of naive, memory and CD28À T cell subsets by three-color flow cytometry in PBPC aphereses harvested following cytotoxic chemotherapy with cyclophosphamide (CTX, bottom plots) or with epirubicin and paclitaxel (ET, top plots). As indicated, naive CD4+ and CD8+ T cells were identified either as CD95ÀCD28+ cells or as CD45RA+CD62L+ cells. When using CD95 vs CD28 staining combination, putative memory CD95+CD28+ and CD28À T cells were also identified. To determine the CD4+ and CD8+ T cell frequencies, the staining combination of mAbs against CD3, CD4, and CD8 (conjugated to CyChromet, FITC, and PE, respectively) was used (not shown here). Thereafter, PBPC were stained with combinations of mAbs against either CD4 or CD8 (conjugated to CyChromet) plus CD95-FITC vs CD28-PE and plus CD45RA-FITC vs CD62L-PE. An electronic gate was set on CD4 + (left column) or bright CD8 + (right column) lymphocytes, and dot plots from representative stainings are shown. Figure 1 , were compared. *Po0.05; **Po0.01.
Naive T cells in PBPC grafts
FF Fagnoni et al showed distinct patterns of reconstitution for each subset considered ( Figure 3) . Remarkably, kinetics of naive T cells in both CD4+ and CD8 subsets, but not those of memory or CD28À T cells (not shown), were significantly accelerated in patients infused with PBPC collected after ET. Moreover, such differences were more pronounced during the early than the late phase of reconstitution after transplantation. These differences between the two groups of patients could not be accounted for by age, since patients treated with CTX were slightly younger (median 48 years, range 33-57) than patients treated with ET (median 55.5 years, range 48-59). Although it could not be excluded that high numbers of T cells in grafts and after HD-ChT could have been related to pretransplant T cell function specific to the patients considered in this study, we favor the hypothesis that the number of naive T cells in PBPC grafts may have a positive impact on early reconstitution.
To verify this assumption, we tested the correlation between total numbers of T cells infused in each patient and each corresponding number of circulating cells at 3 months after HD-ChT (Figure 4) . Consistently, we found a strong correlation between the number of naive, but not memory or CD28-, T cells infused and the log of corresponding circulating cells. It should be noted that this finding is concordant with the concept that circulating T cells represent only a small proportion (1-5%) of the body's T cell pool, 21 and therefore it may suggest a specific relationship between the quantity of the naive T cell subset in PBPC grafts and the numbers of naive T cells circulating in the peripheral blood after autologous PBPC transplantation, perhaps regardless of the cytotoxic pretreatment.
Prevalence of VZV reactivation in patients treated with HD-ChT
Cell-mediated immunity against varicella is reported to be frequently lost in the post-transplantation period. 7 Therefore, patients are usually treated with prophylaxis including acyclovir in the first 3 months to reduce the risk of VZV endogenous reactivation. In particular, in our small group of 10 patients studied prospectively for T cell subpopulations after HD-ChT and autologous PBPC transplantation, we could observe typical VZV vesicular skin lesions with a dermatomal distribution in three patients, of whom two had been infused with CTX-PBPC (out of six considered), and one with ET-PBPC (out of four considered). Thereafter, we looked retrospectively for VZV prevalence in all patients treated with HD-ChT for breast cancer at our institution. Typical VZV reactivation was reported in the first 12 months after transplantation in nine patients out of 102 transplanted for primary high-risk breast cancer with PBPC collected after CTX. In contrast, identical infectious complications were reported only in one patient out of 46 Data are expressed as absolute numbers Â 10 9 of viable cells counted directly after thawing, as reported in the method section. Statistical analysis was obtained by two-tailed Mann-Whitney U-test and differences were considered significant when Po0.05. Figure 3 Comparison of kinetics of circulating naive and memory T lymphocytes after HD-ChT between six patients infused with PBPC harvested after cyclophosphamide (CTX, filled squares) vs four patients infused with PBPC harvested after epirubicin and paclitaxel (ET, in empty circles). Of these latter patients infused with ET-PBPC grafts, two had metastatic breast cancer, and two had primary breast cancer, as indicated in the method section. *Po0.05.
transplanted for metastatic disease with PBPC collected after ET. Although the difference between VZV prevalences from these two small groups of patients could have been related to distinct conditioning regimens and may not be amenable to statistical analysis, these observations would be also compatible with a role played by the quantity and quality of T cells in the two types of graft.
Discussion
In this study, we evaluated the T cell composition of PBPC autologous grafts harvested after two different cytotoxic regimens as well as naive, memory, and CD28À T cell subsets circulating in the peripheral blood of patients treated with HD-ChT and PBPC autologous transplantation. We found that the passive transfer of naive T cells, but not of memory and CD28À T cells, positively correlated to their own reconstitution in the early phase after transplantation. These results contribute to clarifying conflicting data previously reported by others and support the notion that the starting pool of mature naive T cells may undergo proliferative expansion and might have a substantial impact on patients immune recovery in the early phase after HD-ChT.
Originally, our study was based on the unforeseen observation that PBPC grafts harvested after cytotoxic treatment with ET still retained high numbers of T cells with a near-to-normal proportion of the naive subset. Even though the aim of the study was not to evaluate drug immunotoxicity, it should be noted that T cell depletion deriving from treatment with the ET protocol appeared remarkably less profound than that induced by CTX administered as a single agent at high dose intensity. These findings confirm that CTX is highly immunosuppressive, 22 and also suggest that peripheral T cells may have distinct sensitivity to different types of drugs and emphasize the role of cytotoxic treatment administered before PBPC mobilization on the cell composition of PBPC grafts.
Several studies have already reported various findings on the reconstitution of the T cell pool after autologous stem cell transplantation. [1] [2] [3] [4] 11, 12, [23] [24] [25] Nevertheless, the degree of the contribution by T cells contaminating PBPC remains still controversial. 11, 12 . In spite of the small number of patients available for evaluation of naive, memory and CD28À T cells in PBPC and in peripheral blood 90 days after transplantation in our study, we found evidence of discrete relationships occurring for naive, but not for activated T cells (Figures 3 and 4) . Moreover, although limited data were obtained by phenotypic analysis, it should be noted that they were also consistent with homeostasis-driven proliferative expansion observed experimentally in lymphopenic mice. 26, 27 Therefore, assuming that T cells with a naive phenotype contain the largest fraction of the TcR repertoire, 28 it could be speculated that the starting pool of mature T cells may provide a substantial lymphopoietic support to the severe disruption of TcR diversity in the early phase after HD-ChT. 29 The question remains as to whether high numbers of T cells in the grafts may confer not only more rapid T-cell reconstitution, but also better immune competence and perhaps overall prognosis. 30 In fact, following HD-ChT, patients are more susceptible to opportunistic infections and to reactivation of persistent virus after transplantation. 7 When we analyzed the prevalence of infectious complications, surprisingly we found that patients with metastatic disease were apparently less vulnerable to VZV reactivation than patients with primary disease. Apparently, such findings would contradict the common observation that patients with advanced disease may have been heavily pretreated with cytotoxic chemotherapy and possibly they may be less immunocompetent than at earlier stage of disease. Although other factors such as pretransplant T cell function and different conditioning regimens might also account for such a discrepancy between the two groups of patients, we speculate that one further explanation may be provided by different numbers and composi- Figure 4 Correlation between absolute numbers of T cells infused within PBPC grafts and the log of circulating T cells evaluated at 3 months after autologous PBPC transplantation. Analysis was carried out in the same group of patients considered in Figure 3 , plus one additional patient with primary breast cancer, by Spearman's correlation coefficient. Empty circles indicate patients pretreated with CTX and filled circles are for patients pretreated with ET. As shown, the value was significant for naive, but not for memory or CD28À T cells.
tion of T cells in the different types of PBPC grafts administered in the two clinical settings.
On the whole, our study suggests that adoptive transfer of autologous naive T cells may be useful to accelerate kinetics of naive T cell reconstitution after acute T cell lymphopenia induced by HD-ChT. Abbreviation of T cell immunodeficiency could be beneficial especially in patients with poor thymic function. Moreover, regardless of thymic function, patients are not considered eligible for vaccination protocols until approximately 6-12 months after transplantation, thus limiting the possibility to implement protocols of active immunotherapy immediately after HDChT. 31, 32 Therefore, an interesting hypothesis arising from our study, yet to be tested, is whether patients given large numbers of naive T cells may be rendered promptly competent for induction of primary immune responses.
